- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
Malignant Brain Tumor (MBT) domains are a family of methylated lysine-recognizing transcriptional repressors. They possess a methyl-lysine (Kme) binding pocket along with other Kme reader proteins, but MBT domains selectively recognize mono- and dimethylated lysines.
|Cat. No.||Product Name / Activity|
|Potent inhibitor of L3MBTL3 Kme reader domain; cell permeable|
|4516||UNC 926 hydrochloride|
|L3MBTL1 domain inhibitor|
Malignant Brain Tumor (MBT) domains are a family of methylated lysine-recognizing transcriptional repressors. They possess a methyl-lysine (Kme) binding pocket along with other Kme reader proteins, but MBT domains selectively recognize mono- and dimethylated residues over unmethylated and trimethylated lysines.
MBT domains are part of the 'Royal family' of Kme readers, which also includes chromo, Tudor and PWWP domains. Their function has been associated with gene repression, whilst MBTD1, L3MBTL1 and L3MBTL3 are also linked to hematopoiesis. It has also been reported that some MBT domains act as tumor suppressors through an as yet uncharacterized mechanism, and dysregulated MBT domain activity is associated with various diseases such as breast cancer and neurological tumors.
MBT domains can also exist alongside other domains in large chromatin-remodeling complexes, such as polycomb repressor complexes, which regulate gene expression. These multisubunit complexes use the energy from ATP hydrolysis to disrupt the association of histones with DNA, thereby influencing transcription.
Tocris offers the following scientific literature for MBT Domains to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:
|Gene||Species||Gene Symbol||Gene Accession No.||Protein Accession No.|
|MBT domain containing 1||Human||MBTD1||NM_017643||Q05BQ5|